PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Rhea-AI Summary

PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has scheduled its third quarter 2024 financial results announcement for November 13, 2024, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss results and provide business updates. Interested parties can register for the call through the provided link, with registration recommended at least 5 minutes before the start time. For those not planning to ask questions, the company suggests following via webcast.

News Market Reaction – PYPD

+1.43%

1 alert

+1.43% News Effect

On the day this news was published, PYPD gained 1.43%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

PETACH TIKVA, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 13, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, November 13, 2024
Time:	8:30 AM Eastern Time
Conference Call:	https://register.vevent.com/register/BI198de55d5c06495994d35cbb213655eb
Webcast:	https://edge.media-server.com/mmc/p/j6bnvt8c

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Contacts: 

PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
Britchie@lifesciadvisors.com

FAQ

When will PolyPid (PYPD) release Q3 2024 earnings?

PolyPid will release its Q3 2024 earnings before U.S. markets open on Wednesday, November 13, 2024.

What time is PolyPid's (PYPD) Q3 2024 earnings call?

PolyPid's Q3 2024 earnings conference call is scheduled for 8:30 AM Eastern Time on Wednesday, November 13, 2024.

How can I join PolyPid's (PYPD) Q3 2024 earnings call?

You can join the earnings call by registering through the provided link or access the webcast through the company's media server link. Registration is recommended at least 5 minutes before the call.